AUPH Quote, Financials, Valuation and Earnings

Halozyme Therapeutics, Inc. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of 49.46%. Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $16.67, signalling upside risk potential of 8.86%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $76.00 which suggests that it could grow by 20.73%. Given that Halozyme Therapeutics, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Halozyme Therapeutics, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.425, which suggesting that the stock is 42.546% more volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.224%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $73.5M, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. Aurinia Pharmaceuticals, Inc.'s net income of $31.6M is lower than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 27.29x while Halozyme Therapeutics, Inc.'s PE ratio is 13.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 8.13x versus 6.36x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of -2178.51%. Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $16.67, signalling upside risk potential of 8.86%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 376.19%. Given that Lexaria Bioscience Corp. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.425, which suggesting that the stock is 42.546% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $73.5M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. Aurinia Pharmaceuticals, Inc.'s net income of $31.6M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 27.29x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 8.13x versus 28.57x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of --. Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $16.67, signalling upside risk potential of 8.86%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 459.36%. Given that Oncolytics Biotech, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.425, which suggesting that the stock is 42.546% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $73.5M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Aurinia Pharmaceuticals, Inc.'s net income of $31.6M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 27.29x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 8.13x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of -867.29%. Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $16.67, signalling upside risk potential of 8.86%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.19 which suggests that it could grow by 23.72%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.425, which suggesting that the stock is 42.546% more volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $73.5M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Aurinia Pharmaceuticals, Inc.'s net income of $31.6M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 27.29x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 8.13x versus 468.81x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.